X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK LTD vs DIVIS LABORATORIES - Comparison Results

MERCK LTD    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK LTD DIVIS LABORATORIES MERCK LTD/
DIVIS LABORATORIES
 
P/E (TTM) x 50.4 38.4 131.2% View Chart
P/BV x 7.6 6.2 122.2% View Chart
Dividend Yield % 0.4 0.7 51.6%  

Financials

 MERCK LTD   DIVIS LABORATORIES
EQUITY SHARE DATA
    MERCK LTD
Dec-16
DIVIS LABORATORIES
Mar-18
MERCK LTD/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,0601,142 92.8%   
Low Rs623533 116.9%   
Sales per share (Unadj.) Rs632.4146.6 431.4%  
Earnings per share (Unadj.) Rs45.733.0 138.4%  
Cash flow per share (Unadj.) Rs62.338.4 162.3%  
Dividends per share (Unadj.) Rs11.0010.00 110.0%  
Dividend yield (eoy) %1.31.2 109.5%  
Book value per share (Unadj.) Rs388.8222.8 174.5%  
Shares outstanding (eoy) m16.60265.47 6.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.35.7 23.3%   
Avg P/E ratio x18.425.3 72.6%  
P/CF ratio (eoy) x13.521.8 61.9%  
Price / Book Value ratio x2.23.8 57.6%  
Dividend payout %24.130.3 79.5%   
Avg Mkt Cap Rs m13,969222,318 6.3%   
No. of employees `0001.610.8 14.7%   
Total wages/salary Rs m1,4874,561 32.6%   
Avg. sales/employee Rs Th6,631.93,616.0 183.4%   
Avg. wages/employee Rs Th939.2423.8 221.6%   
Avg. net profit/employee Rs Th479.4814.9 58.8%   
INCOME DATA
Net Sales Rs m10,49838,915 27.0%  
Other income Rs m2421,134 21.4%   
Total revenues Rs m10,74140,049 26.8%   
Gross profit Rs m1,13512,617 9.0%  
Depreciation Rs m2761,425 19.3%   
Interest Rs m013 0.0%   
Profit before tax Rs m1,10212,313 9.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3433,543 9.7%   
Profit after tax Rs m7598,770 8.7%  
Gross profit margin %10.832.4 33.4%  
Effective tax rate %31.128.8 108.2%   
Net profit margin %7.222.5 32.1%  
BALANCE SHEET DATA
Current assets Rs m6,41045,351 14.1%   
Current liabilities Rs m8,8286,507 135.7%   
Net working cap to sales %-23.099.8 -23.1%  
Current ratio x0.77.0 10.4%  
Inventory Days Days58127 45.5%  
Debtors Days Days3895 40.3%  
Net fixed assets Rs m1,40621,160 6.6%   
Share capital Rs m166531 31.3%   
"Free" reserves Rs m6,28658,625 10.7%   
Net worth Rs m6,45559,156 10.9%   
Long term debt Rs m00-   
Total assets Rs m8,82867,832 13.0%  
Interest coverage xNM926.8-  
Debt to equity ratio x00-  
Sales to assets ratio x1.20.6 207.3%   
Return on assets %8.612.9 66.4%  
Return on equity %11.814.8 79.3%  
Return on capital %17.120.8 81.9%  
Exports to sales %8.30-   
Imports to sales %21.021.8 96.5%   
Exports (fob) Rs m869NA-   
Imports (cif) Rs m2,2098,485 26.0%   
Fx inflow Rs m95932,359 3.0%   
Fx outflow Rs m2,6129,042 28.9%   
Net fx Rs m-1,65323,317 -7.1%   
CASH FLOW
From Operations Rs m1,0707,759 13.8%  
From Investments Rs m-750-4,783 15.7%  
From Financial Activity Rs m-150-3,142 4.8%  
Net Cashflow Rs m171-166 -103.0%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 11.8 154.2%  
FIIs % 1.0 19.0 5.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 17.2 169.2%  
Shareholders   28,591 31,796 89.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK LTD With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  STRIDES SHASUN LTD  TTK HEALTHCARE  

Compare MERCK LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

MERCK LTD Announces Quarterly Results (1QFY19); Net Profit Up 63.1% (Quarterly Result Update)

Aug 8, 2018 | Updated on Aug 8, 2018

For the quarter ended June 2018, MERCK LTD has posted a net profit of Rs 328 m (up 63.1% YoY). Sales on the other hand came in at Rs 2 bn (down 17.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Sep 19, 2018 (Close)

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MERCK LTD - TTK HEALTHCARE COMPARISON

COMPARE MERCK LTD WITH

MARKET STATS